Economy

Behind Trump's enthusiastic support for PM Takaichi lies growing frustration over delayed Japanese investments in America

The Bank of Japan starts unwinding its massive $610 billion ETF holdings in a process that could reshape Japanese corporate governance and global markets for generations.

Morgan Stanley's first bitcoin miner coverage reveals a stark divide - data center converters get buy ratings while pure miners face sell recommendations. A new paradigm for crypto infrastructure?

The White House is already setting expectations low for this week's jobs report. Here's why the 69K forecast matters more than the headline suggests, and what investors should watch.

CNBC's Jim Cramer speculated about government bitcoin purchases at $60,000, but Trump's promised strategic reserve lacks congressional approval and legal framework for taxpayer-funded crypto buying.

MegaETH debuts targeting 100K+ transactions per second, entering heated debate over Ethereum scaling. Can blockchain finally feel like web apps?

Scottish Labour leader demands PM Starmer step down just six months into his tenure, exposing deep fractures within the ruling party and raising questions about Labour's future direction.

Thailand's ruling Bhumjaithai Party secured an unexpected landslide victory in Sunday's election, marking a significant shift in Southeast Asian politics and offering insights into modern electoral dynamics.

Wall Street slides as AI investment concerns mount ahead of crucial economic data. Analyzing what this means for investors and the broader market.

Databricks raises $5B at $134B valuation, delaying IPO amid market uncertainty. Analysis of AI unicorn's strategy and implications for tech IPO market in 2026

Monday.com plunged 19% after weak guidance amid AI disruption fears. Software ETF down 22% this year as agentic AI tools threaten traditional business models. CEO claims no AI impact but pivots strategy.

Novo Nordisk sues Hims & Hers over knockoff weight-loss drugs. A David vs Goliath battle over patient access versus Big Pharma patents unfolds.